I am a
Home I AM A Search Login

Papers of the Week

2020 Apr

J Can Assoc Gastroenterol



Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness.


Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart HA, Silverberg MS
J Can Assoc Gastroenterol. 2020 Apr; 3(2):74-82.
PMID: 32328546.


Vedolizumab (VDZ) is a humanized monoclonal IgG1 antibody which inhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade.